Colloidal Dispersions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222. -
Syntheses and Biological Activity of Sparsomycin and Analogs
SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE ROB M.J. LISKAMP SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE Promotor : Prof. Dr. R.J.F. Nivard Co-referent : Dr. H.C.J. Ottenheijm SYNTHESES AND BIOLOGICAL ACTIVITY OF SPARSOMYCIN AND ANALOGS THE CHEMISTRY OF CHIRAL FUNCTIONALIZED SULFOXIDES AND SULTINES DERIVED FROM CYSTEINE PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE WISKUNDE EN NATUURWETENSCHAPPEN AAN DE KATHOLIEKE UNIVERSITEIT VAN NIJMEGEN OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. J.H.G.I. GIESBERS VOLGENS HET BESLUIT VAN HET COLLEGE VAN DEKANEN IN HET OPENBAAR TE VERDEDIGEN OP VRIJDAG 10 DECEMBER 1982 DES NAMIDDAGS OM 4 UUR DOOR ROBERTUS MATTHIAS JOSEPH LISKAMP GEBOREN TE NIJMEGEN NIJMEGEN 1982 Dit proefschrift vormt de neerslag van vier jaar wetenschappelijk onderzoek. Ik wil iedereen - en dat waren er zeer velen - bedanken, die hieraan gedurende die tijd door hun stimulerende discussie of door de feitelijke uitvoering deel hadden. Zij gaven mede richting en vorm, niet alleen organisch maar ook biochemisch/biologisch en fysisch chemisch, aan het verrichte onderzoek. Daarnaast wil ik hen bedanken die een bijdrage geleverd hebben aan de onmis bare technische uitvoering van het in dit proefschrift beschreven onderzoek. En tenslotte wil ik ook hen bedanken die aan de vormgeving van het proef schrift hun medewerking hebben verleend. Tekeningen : Wim van Luijn en de afdeling illustratie Type-werk : Dorine Hesselink-Balvert Afbeelding op de omslag: Een 'stacked plot' van een 2D-spin-echo correlated spectrum van synthetisch sparsomycine verzorgd door Wim Guijt This research was supported by the Netherlands Foundation for Chemical Research (SON) with financial aid from the Netherlands Organization for the Advancement of Pure Research (ZWO). -
(12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun. -
Phytochem Referenzsubstanzen
High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.286. ABIETIC ACID Sylvic acid [514-10-3] 302.46 C20H30O2 01.030. L-ABRINE N-a-Methyl-L-tryptophan [526-31-8] 218.26 C12H14N2O2 Merck Index 11,5 01.031. (+)-ABSCISIC ACID [21293-29-8] 264.33 C15H20O4 Merck Index 11,6 01.032. (+/-)-ABSCISIC ACID ABA; Dormin [14375-45-2] 264.33 C15H20O4 Merck Index 11,6 01.002. ABSINTHIN Absinthiin, Absynthin [1362-42-1] 496,64 C30H40O6 Merck Index 12,8 01.033. ACACETIN 5,7-Dihydroxy-4'-methoxyflavone; Linarigenin [480-44-4] 284.28 C16H12O5 Merck Index 11,9 01.287. ACACETIN Apigenin-4´methylester [480-44-4] 284.28 C16H12O5 01.034. ACACETIN-7-NEOHESPERIDOSIDE Fortunellin [20633-93-6] 610.60 C28H32O14 01.035. ACACETIN-7-RUTINOSIDE Linarin [480-36-4] 592.57 C28H32O14 Merck Index 11,5376 01.036. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- a-D-Glucosamine pentaacetate 389.37 C16H23NO10 ACETYL-a-D-GLUCOPYRANOSE 01.037. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- b-D-Glucosamine pentaacetate [7772-79-4] 389.37 C16H23NO10 ACETYL-b-D-GLUCOPYRANOSE> 01.038. 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL- Acetochloro-a-D-glucosamine [3068-34-6] 365.77 C14H20ClNO8 a-D-GLUCOPYRANOSYLCHLORIDE - 1 - High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.039. -
United States Patent (19) 11 Patent Number: 5,753,634 Ebetino Et Al
USOO5753634A United States Patent (19) 11 Patent Number: 5,753,634 Ebetino et al. 45 Date of Patent: May 19, 1998 54 QUATERNARY NITROGEN CONTAINING 4.011777 10/1990 Germany. PHOSPHONATE COMPOUNDS, WO 90/12017 10/1990 WIPO PHARMACEUTICAL COMPOSTIONS, AND WO 91/10646 7/1991 WIPO. METHODS FOR TREATING ABNORMAL Primary Examiner-Amelia Owens CALCUMAND PHOSPHATE METABOLISM Attorney, Agent, or Firm-Richard A. Hake; Karen F. Clark; William J. Winter 75 Inventors: Frank Hallock Ebetino; Marion David Francis, both of Cincinnati, 57 ABSTRACT Ohio; Susan Mary Kaas, Sherburne, Disclosed are quaternary nitrogen-containing, saturated or N.Y. unsaturated monocyclic and bicyclic ring-containing bis 73 Assignee: The Procter & Gamble Company, phosphonate compounds, and pharmaceutically-acceptable Cincinnati, Ohio salts and esters thereof. These compounds, which are useful for treating or preventing disorders of calcium and phos 21) Appl. No.: 52,694 phate metabolism, have the following general structure: 22) Filed: Apr. 30, 1993 (R), (CR2), (CR,): NY R Related U.S. Application Data 63 Continuation-in-part of Ser. No. 891,487, May 29, 1992, abandoned. 51 Int. Cl. ... A61K 31/675; A61K 31/66 52) U.S. Cl. ............................ 514/81: 514/91; 514/109: wherein 546/23: 548/111; 562/21 (a) each X and Y are independently selected from nil, O, 58 Field of Search ............................... 546/23: 514/80, S, NR' and N*(R); if no R' is N'(R), then at least 514/82, 91, 109; 548/111; 562/21 one of X or Y must be N(R); References Cited (b) m and n and m+n are integers from 0 to 5; p and q and 56 p+q are integers from 0 to 3; U.S. -
Tepzz 459659B T
(19) TZZ _T (11) EP 2 459 659 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: C09D 7/00 (2006.01) C09D 7/14 (2006.01) of the grant of the patent: C09D 5/16 (2006.01) 17.07.2013 Bulletin 2013/29 (86) International application number: (21) Application number: 10737728.5 PCT/US2010/043382 (22) Date of filing: 27.07.2010 (87) International publication number: WO 2011/017097 (10.02.2011 Gazette 2011/06) (54) REMOVABLEANTIMICROBIAL COATING COMPOSITIONS CONTAINING CATIONIC RHEOLOGY AGENT AND METHODS OF USE ABLÖSBARE ANTIMIKROBIELLE BESCHICHTUNGSZUSAMMENSETZUNGEN MIT KATIONISCHEM RHEOLOGISCHEM ADDITIV UND ANWENDUNGSVERFAHREN COMPOSITIONS DE REVÊTEMENT ANTIMICROBIENNES, APTES À ÊTRE RETIRÉES, CONTENANT UN AGENT DE RHÉOLOGIE CATIONIQUE, ET PROCÉDÉS D’UTILISATION (84) Designated Contracting States: (74) Representative: Dannenberger, Oliver Andre et al AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abitz & Partner GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Patentanwälte PL PT RO SE SI SK SM TR Postfach 86 01 09 81628 München (DE) (30) Priority: 27.07.2009 US 228707 P 27.07.2009 US 228711 P (56) References cited: 27.07.2009 US 228715 P WO-A2-2007/100653 WO-A2-2007/100654 27.07.2009 US 228723 P 26.07.2010 US 843120 • Akzo Nobel Surface Chemistry: "Thickening with polymers"[Online] 1 January 2010 (2010-01-01), (43) Date of publication of application: XP002609717 Akzo Nobel Technical Information 06.06.2012 Bulletin 2012/23 Retrieved from the Internet: URL:http: //www.akzonobel.com/surface/syste m/images/ (73) Proprietor: E. -
(12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct. -
Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration. -
Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Updated July 30, 2020 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Notice of Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List • Additions to category 1: Betahistine Hydrochloride L-Proline Citrulline Papaverine Hydrochloride* Copper Gluconate Phosphatidylcholine Diiodohydroxyquinoline Podophyllum Resin Glucosamine Sulfate Potassium Chloride Sodium Molybdate Glucosamine Sulfate Sodium Chloride Sodium Nitroprusside Hydrochloric Acid* Sodium Selenite/Sodium Selenite Pentahydrate* Ibutamoren Mesylate Trichloroacetic Acid* L-Citrulline* Ubidecarenone (Coenzyme Q10)* L-Lysine * Bulk drug substance is currently in Category 3 and is being moved to Category 1. • Minor revision to entry in Category 1 to correct a misspelling: o Correct the misspelling of “cimatidine” to “cimetidine” 1 Updated July 30, 2020 503B Category 1: Bulk Drug Substances Under Evaluation • 5-Methyltetrahydrofolate Calcium • Chromic Chloride • 17-alpha-Hydroxyprogesterone • Chromium chloride/ Chromium Chloride • Acetylcysteine Hexahydrate • Acyclovir • Ciclopirox Oleate • Adapalene • Cimetidine • Adenosine • Ciprofloxacin HCl • Allantoin • Citric Acid Anhydrous • Alpha Lipoic Acid • Citrulline/L-Citrulline • Alprostadil • Clindamycin Phosphate -
(12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 Rozzell Et Al
US 20060275279A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 ROZZell et al. (43) Pub. Date: Dec. 7, 2006 (54) METHODS FOR DISSOLVING CYSTINE (22) Filed: Jun. 6, 2005 STONES AND REDUCING CYSTINE IN URINE Publication Classification (76) Inventors: J. David Rozzell, Burbank, CA (US); (51) Int. Cl. Kavitha Vedha-Peters, Pasadena, CA A6II 38MSI (2006.01) (US) (52) U.S. Cl. ............................................................ 424/94.5 Correspondence Address: CHRISTIE, PARKER & HALE, LLP (57) ABSTRACT PO BOX 7O68 PASADENA, CA 91109–7068 (US) The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase (21) Appl. No.: 11/146,551 to increase the rate of cystine Stone dissolution. Patent Application Publication Dec. 7, 2006 Sheet 1 of 4 US 2006/0275279 A1 Hs1N1 Ncoh L-Homocysteine -- H2 O HOC n1ns 1-1N CO2H Cystathionine?3-lyase ls CO2H H2 Pyruvate L-Cystathionine H NH FIG. 1. Metabolic Reaction Catalyzed by Cystathionine-?s-Lyase Patent Application Publication Dec. 7, 2006 Sheet 2 of 4 US 2006/0275279 A1 NH2 Hs1 S Y1Ncoh L-Thiocysteine -- NH2 O Hozen-1- 1N1 no H Cystathionine e i 2 B-lyase CO2H NH2 P L-CystineA- y ruvate -- NH FIG. 2. "Un-Natural" Reaction Catalyzed by Cystathionine-?s-Lyase on L-Cystine Patent Application Publication Dec. 7, 2006 Sheet 3 of 4 US 2006/0275279 A1 Dissolution of Cystine Stones with Cystathionine beta-lyase (MetC) s -o-control (no MetC) al -H 1 mg/mL MetC g - 5 mg/mL MetC 3. -- 10 mg/mL MetC S. -
Assessment of the Antibiotic Resistance Effects of Biocides
Scientific Committee on Emerging and Newly Identified Health Risks SCENIHR Assessment of the Antibiotic Resistance Effects of Biocides The SCENIHR adopted this opinion at the 28th plenary on 19 January 2009 after public consultation. 1 Antibiotic Resistance Effects of Biocides About the Scientific Committees Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), and are made up of external experts. In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA). SCENIHR Questions concerning emerging or newly-identified risks and on broad, complex or multi- disciplinary issues requiring a comprehensive assessment of risks to consumer safety or public health and related issues not covered by other Community risk-assessment bodies. In particular, the Committee addresses questions related to potential risks associated with interaction of risk factors, synergic effects, cumulative effects, antimicrobial resistance, new technologies such as nanotechnologies, medical devices, tissue engineering, blood products, fertility reduction, cancer of endocrine organs, physical hazards such as noise and electromagnetic fields and methodologies for assessing new risks. -
Copyrighted Material
Index Abhexon, 501, 565 bitter, 636 reactions, 564, 565 dimethylarsinoyl, 415 Abietadiene, 505, 506 oxocarboxylic, 550 Abietic acid, 189 phenolic, 551 Absinthin, 634 reactions, 555 Acacetin, 695 sugar, 212 Acacipetalin, 775, 776 Acidulants, 872 Acenaphthene, 919 Aconitic acid, 546 Acenaphthylene, 919 Acorin, 635 Acephate, 1010 Acrolein, 82 Aceric acid, 213, 214, 259 reactions, 180, 181, 193, 527, 538 Acesulfame K, 865, 866, 870 Acromelic acids, 829 Acetaldehyde, 72, 527 Acrylamide, 899, 900 reactions, 295, 538, 540 content in foods, 900 Acetals, 537, 541 reactions, 901, 902 reactions, 538 Acrylic acid, 1034 Acetic acid, 542, 850 Acrylonitrile, 1039 reactions, 296, 297, 543 Actin, 47 Acetoacetic acid, 551 Actinin, 47 Acetoin, 522, 536 Acylchloropropanediols, 910 reactions, 522 Acyloins, 536 Acetol, see hydroxyacetone Acylsphingosines, see ceramides Acetone, 533 Additives, 847 reactions, 540 Adenine, 396, 397 Acetophenone, 535 Adenosine diphosphate, see ADP Acetylcholine, 399 monophosphate, see AMP Acetylcysteines, see mercapturates triphosphate, see ATP Acetylfuran, 286 Adenylic acid, see AMP Acetylgalactosamine, 53, 58 Adermine, see vitamin B6 Acetylglucosamine, 58 Adhesives, 889 Acetylhistidines, 20 Adhyperflorin, 712 Acetyllactaminic acid, see acetylneuraminic acid Adipic acid, 544 Acetyllysine, 18 ADP, 18, 874 Acetylmuramic acid, 217 Adrastin, 951 Acetylneuraminic acid, 53, 58, 217 COPYRIGHTEDAdrenaline, MATERIALsee epinephrine Acetylpyridine, 590 Adriatoxin, 838 Acetylpyrroline, 18, 501 Advanced glycation end products, 319–23 Acetylpyrroline, reactions, 599 lipoxidation end products, 319 Acetyltetrahydropyridine, 18 Aflatoxicol, 946 Acetyltetrahydropyridine, reactions, 600 Aflatoxins, 942, 945–8 Acids as preservatives, 848 Aflatrem, 961 lipoamino, 129 Afzelechins, 648 aldonic, 212 Agar, 269 alicyclic, 551 Agaric acid, see agaricinic acid aromatic, 551 Agaricinic acid, 835, 865 bile, 140 Agaricone, 705 The Chemistry of Food, First Edition.